**Core tip:** A patient on peritoneal dialysis who received an overdose of anti-virals showed severe mental disorders. Peritoneal dialysis and continuous renal replacement therapy did not improve the symptoms. Hemodialysis is recommended to remove excess drugs.

INTRODUCTION
============

Herpes zoster occurs upon reactivation of varicella zoster virus and is characterized by pain and blistering skin eruption with dermatomal distribution\[[@B1]-[@B4]\]. The occurrence of herpes zoster increases with decline in T-cell-mediated immunity, which may occur with age or immunosuppression\[[@B1]-[@B4]\]. The rash typically resolves in 2-4 wk, but nerve pain may continue for months to years\[[@B1],[@B3]\]. Beside pain management, anti-retroviral drugs can be used in patients without response to topical anti-retroviral, age ≥ 50 years, moderate to severe pain, severe rash, and/or non-truncal involvement\[[@B2],[@B4]\]. The common drugs include valacyclovir, acyclovir, foscarnet, and bruvudin\[[@B2]\]. Compared with acyclovir, valacyclovir has advantages such as better oral effectiveness and tolerance, high water solubility, and less adverse reactions. Valacyclovir rapidly transforms into acyclovir after entering the body. Its common side effects include nausea, vomiting, and discomfort\[[@B5]\].

One possible, albeit rare, side effect of anti-retroviral drugs is central nervous system toxicity, which has been described since the 1980s\[[@B6]-[@B9]\]. The symptoms in patients with previously normal brain function may include visual hallucinations, death delusion, tremor, and coma, with onset of 24-72 h after starting acyclovir\[[@B8]\]. The symptoms are possibly due to a metabolite of acyclovir that is found at high levels in the cerebrospinal fluid of patients with neuropsychiatric symptoms\[[@B10]\]. Since 90% of acyclovir is cleared by the kidneys, patients with chronic kidney disease have increased serum half-life of acyclovir\[[@B11]\]. Most patients with neuropsychiatric disorders under acyclovir treatment have renal function impairment\[[@B10]\].

We present one patient on peritoneal dialysis who suffered from severe mental disorders after taking an overdose of antiviral drugs for herpes zoster. The patient died after his consciousness did not improve after peritoneal dialysis and continuous blood purification.

CASE PRESENTATION
=================

Chief complaints
----------------

A 65-year-old man on peritoneal dialysis was referred to our hospital in July 2018 with complaints of blisters on the left frontal area with pain, and unstable walking and hallucinations.

History of present illness
--------------------------

The patient felt severe pain in the left frontal face, with blisters for 6 d, and was diagnosed with herpes zoster. He was given antiviral treatment with intravenous acyclovir 0.5 g qd and dexamethasone 5 mg qd to relieve pain (continuous treatment for 3 d). The dermatologist prescribed oral valacyclovir 0.3 g bid after 3 d. Nonetheless, the patient misunderstood the recommendation, and received acyclovir and valacyclovir simultaneously. After 2 d of treatment, the local facial pain was relieved, and the blisters became stable, but he became with unstable walking and involuntary shaking of the limbs, accompanied by hallucinations (irregular fluttering of objects when the eyes were closed), irritability, and lethargy. He denied fever, loss of consciousness, epilepsy, suicidal or homicidal ideation, and a sudden stop of dialysis. Before onset, the patient had mild temperament and took care of himself in the daily life.

History of past illness
-----------------------

The patient had a history of hypertension for more than 10 years, under control using nifedipine controlled release tablets 30 mg bid and valsartan 80 mg bid.

He was diagnosed with idiopathic chronic renal failure (stage 5). He had been receiving peritoneal dialysis treatment for 3 years. He was anuretic at admission using peritoneal dialysis solution with 2.5% calcium glucose 2000 mL × 4 bags, continuous ambulatory peritoneal dialysis (CAPD), with an ultrafiltration of 1200 mL/d.

Personal and family history
---------------------------

The patient denied any personal or family history of diseases.

Physical examination upon admission
-----------------------------------

On admission, the body temperature 37.2 °C, pulse 107 bpm, breathing 20/min, blood pressure 175/108 mmHg, intermittent mild disturbance of consciousness, and with visible scattered red blister rash in the left eyelid and left forehead, which was protruded and tender, but otherwise with normal superficial lymph nodes and cardiopulmonary examinations. Nervous system examination showed negative Pap\'s sign but normal muscle tension in limbs.

Laboratory examinations
-----------------------

The laboratory examinations showed: White blood cells 7.8 × 10^9^/L, hemoglobin 86 g/L, albumin 28 g/L, creatinine 1146 µmol/L, urea nitrogen 21.6 mmol/L, uric acid 277 µmol/L, potassium 4.2 mmol/L, sodium 145 mmol/ L, chlorine 100 mmol/L, PO~2~ 43 mmHg, TCO~2~ 24 mmol/L, glucose 4.7 mmol/L, and iPTH 313 pg/mL. Dialysis adequacy: KT/V = 1.64 (1 mo ago), Ccr= 41.4 L/wk. The electrocardiogram showed normal sinus rhythm. The lumbar puncture showed: Cerebrospinal fluid pressure 155 mmH~2~O, proteins 542 mg/L, glucose 4.64 mmol/L, chlorine 121.7 mmol/L (no abnormality), and negative bacteria and tuberculosis.

Imaging examinations
--------------------

There were no obvious abnormalities in head and chest computed tomography (CT) as well as head magnetic resonance imaging (MRI).

FINAL DIAGNOSIS
===============

Based on the laboratory test results and imaging examinations, the differential diagnoses of cerebrovascular accidents, viral encephalitis and uremia encephalopathy were ruled out. Since he had a clear history of overdose of antiviral drugs 6 days prior to the onset of the psychiatric symptoms, the patient was finally diagnosed as mental disorders caused by antiviral drugs.

TREATMENT
=========

Immediately after admission, valacyclovir was discontinued, the peritoneal fluid was increased to 5 bags/d, 2000 mL per bag, and CAPD mode, and the blood pressure was dropped to around 150-160/90 mmHg after antihypertensive treatment with Adalat 30 mg bid, valsartan 80 mg bid and perindopril 8 mg qd. After 2 d of treatment, the involuntary limb shaking was not relieved and the disturbance of consciousness progressively aggravated (drowsiness-delirium-coma). On the third day after admission (July 31, 2018), the patient\'s respiratory failure worsened, blood gas analysis showed: pH 7.18, PO~2~ 81 mmHg (oxygen), and PaCO~2~ 77 mmHg, revealing carbon dioxide retention and type 2 respiratory failure. After intubation and respiratory support, the patient was transferred to the intensive care unit (ICU) on the fourth day after admission. In the ICU, peritoneal dialysis was discontinued and continuous renal replacement therapy (CRRT) was started.

OUTCOME AND FOLLOW-UP
=====================

Though given positive rescue treatment, the patient's consciousness was not improved. The patient died 6 d after admission.

DISCUSSION
==========

Herpes zoster usually develops in patients with compromised immune function. Patients on dialysis are at high risk of Herpes zoster. Both valacyclovir and acyclovir are considered to have strong inhibitory effects on types 1 and 2 herpes virus and varicella herpes virus\[[@B12]\]. Valacyclovir is a precursor of acyclovir, which is converted to acyclovir by the liver. Compared with acyclovir, it has the advantages of higher absorption rate, more better pharmacokinetics and pharmacodynamics, and lower frequency of use\[[@B5]\].

The neurotoxicity of acyclovir was reported as early as the 1980s\[[@B6]-[@B9]\]. The clinical manifestations include consciousness disorders and hallucinations, fantasy, insomnia, photoallergies, dysarthria, paresthesia, and coma\[[@B13]-[@B17]\]. If uremia patients develop neuropsychiatric symptoms during anti-retroviral treatment, it is especially important to promptly identify and discontinue the suspicious drugs. Clinicians tend to overlook drug-induced neuropsychiatric disorders. The patient had a history of excessive use of antiviral drugs and showed obvious neuropsychiatric symptoms, despite normal head CT and MRI, and lumbar puncture and cerebrospinal fluid examination. In the present report, the patient had limb shaking, visual hallucinations, and severe disturbances of consciousness, and these symptoms progressively aggravated, which is very rare.

Valacyclovir-associated neurotoxicity usually occurs within 48-72 h of treatment start, and the symptoms can be gradually relieved after the drug is discontinued for 4-14 d (Table [1](#T1){ref-type="table"}). For the patient in the present study, the time of onset and duration of symptoms were similar to those reported in literature\[[@B14],[@B16]-[@B25]\] (Table [1](#T1){ref-type="table"}).

###### 

The reported cases of acyclovir/valacyclovir neurotoxicity in the literature

  **Author**                           **Year of publication**   **Patient**   **Stage of CKD**                 **Renal replacement manner**             **Dosage (mg/d)**                                                               **Duration of antiviral treatment**        **Concomi-tant medication**                                       **Neuropsy-chiatric symptoms**                                                                      **Outcome**
  ------------------------------------ ------------------------- ------------- -------------------------------- ---------------------------------------- ------------------------------------------------------------------------------- ------------------------------------------ ----------------------------------------------------------------- --------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------
  Pipili et al\[[@B18]\]               2013                      Female/72     ESRD                             PD                                       Valacyclovir tablets 3 g daily for 3 d                                          3 d                                        Nifedipine, irbesartan, cinacalcet, atorvastatin, alfacalcidol    Confusion and visual hallucinations                                                                 3 d, restored after PD 6 × 2 L per day
  Chaudhari et al\[[@B16]\]            2014                      Male/66       ESRD                             PD                                       Oral valacyclovir 1000 mg daily for 7 d                                         7 d                                        Simvastatin, metoprolol, sevelamer, furosemide, and glimepiride   Hallucination, insomnia, and photosensi-tivity                                                      7 d, improved after regular regimen and hydration
  Asahi et al\[[@B17]\]                2009                      Female/78     Without previous renal failure   NO                                       Valacyclovir 3000 mg/d                                                          6 d                                        Not mentioned                                                     Unconsciou-sness                                                                                    5 d, recovered 14 d later
  Asahi et al\[[@B17]\]                2009                      Male/73       ESRD                             Hemodialysis                             Valacyclovir 3000 mg/d                                                          2 d                                        Not mentioned                                                     Confusion, hallucination                                                                            2 d, completely recovered 3 d later
  Singh et al\[[@B19]\]                2014                      Female/58     ESRD                             HD                                       Valacyclovir 500 mg/d                                                           2 d                                        Not mentioned                                                     Altered sensorium, irritability, drowsiness, confusion                                              2 d, completely recovered 5 d later
  Kambham-pati et al\[[@B20]\]         2011                      Female/49     ESRD                             Maintenance hemodialysis                 Valacyclovir 1000 mg three times a day                                          2 d                                        Not mentioned                                                     Disoriented, confused, agitated, hallucinating, delirious, incoherent                               1 d, 4000 mg, completely recovered after second session of hemodialysis
  Prasad et al\[[@B14]\]               2017                      Female/57     ESRD                             PD                                       1000 mg three times per day of valacyclovir                                     3 d                                        Not mentioned                                                     Confusion and altered sensorium                                                                     1 day, completely recovered 24 h later
  Izzedine et al\[[@B21]\]             2001                      Female/60     ESRD                             PD                                       Valacyclovir 500 mg daily                                                       Reduced 500 mg of valacyclovir every 2 d   Not mentioned                                                     Disorientated with ocular and auditory hallucinations and loss of decorum without torpor or coma.   3 d, recovered 48 h later
  Strumia et al\[[@B22]\]              2004                      Male/81       ESRD                             Hemodialysis                             Oral valacyclovir 1000 mg every 8 h then intravenous acyclovir in full dosage   3 d                                        Not mentioned                                                     Visual hallucination, confusion and disorientation                                                  3 daysd completely recovered 6 d later
  Linssen-Schuurmans et al\[[@B23]\]   1998                      Male/58       CKD                              Intermittent hemodialysis twice a week   Valacyclovir 3 g/d                                                              2 d                                        Not mentioned                                                     Dizziness, hallucinations, loss of decorum, disoriented, slurred speech                             1 d, complete recovery
  Takayanagi et al\[[@B24]\]           2010                      Male/67       ESRD                             PD                                       Valacyclovir, 1 g/d                                                             5 d                                        Not mentioned                                                     Hallucina-tions                                                                                     7 d, complete recovery
  Sadjadi et al\[[@B25]\]              2018                      Male/80       ESRD                             PD                                       Acyclovir 5 mg/kg intravenously, followed by oral acyclobir 400 mg/d            3 d                                        Not mentioned                                                     Confusion, delusion, disorientation, restlessness, visual hallucinations, seizures                  2 d, complete recovery

CKD: Chronic kidney disease; ESRD: End-stage renal disease; PD: Peritoneal dialysis.

Since acyclovir is mainly cleared by the kidneys, it is a consensus to reduce its dose in patients with renal failure\[[@B25]\]. The dose is mainly determined by a combination of factors such as different methods of dialysis, residual renal function, hydration, and age. The dose of drug used in many cases of neurotoxicity is often greater than the recommended dose\[[@B11],[@B24]\]. It is generally believed that a concentration of acyclovir of 2.5-4.5 µg/mL\[[@B26]\] or a concentration of its main metabolite, carboxymethoxy methylguanine, above 10.8 µmol/L\[[@B10]\] in plasma leads to neurotoxicity. Nevertheless, there is still no consensus on the specific numerical reference range of therapeutic and toxic doses of such drugs, and it is difficult to measure the drug levels in clinical practice.

In the case reported here, increasing the dose of peritoneal dialysis and retention time still could not alleviate the clinical symptoms. Acyclovir and valacyclovir are both soluble and low-protein-bound drugs. In terms of the effectiveness of valacyclovir, a single hemodialysis for 6 h can remove about 60% of the drug, while it is considered to have poor clearance by peritoneal dialysis. On the other hand, case reports suggested that peritoneal dialysis with continuous perfusion of super-dose peritoneal dialysis solution can promote the clearance of valacyclovir\[[@B13],[@B21],[@B24],[@B27]\]. Studies have shown that in patients with normal renal function, 89% of valacyclovir can be cleared from the urine in the form of acyclovir after 2.5-3.3 h, while the half-life of the drug is extended to 14-20 h in patients receiving CAPD for uremia (4 × 2 L exchange dose), and only 5.27 mL/min (0.355 L/h/1.73 m^2^) can be cleared by peritoneal dialysis\[[@B21],[@B27]\]. After a 6-h hemodialysis, the hemodialysis clearance rate of acyclovir is up to 113 mL/min and the plasma drug concentration can be reduced by 61.6%. Therefore, hemodialysis is at least 20 times better than peritoneal dialysis in terms of clearance effect. Based on the large differences in clearance rates between the two dialysis methods, it is suggested to switch peritoneal dialysis to hemodialysis to increase the effect of drug clearance\[[@B20],[@B24],[@B28]\]. Nevertheless, when neurotoxicity occurs, the expected improvement of neurotoxicity by hemodialysis may be delayed, even for a few days. Kageyama et al\[[@B29]\] reported a 75-year-old hemodialysis male who presented with hallucinations, dysarthria, and psychotic symptoms after intravenous acyclovir with reduced dose, which further indicates that the dose adjustment of these drugs is difficult and needs to be comprehensively individualized. CRRT has a good effect on clearing drugs with middle-and-large molecular weight or high protein binding rate. Meanwhile, valacyclovir and acyclovir are soluble and have a low protein binding rate, but there is a lack of literature on the efficacy of CRRT in clearing acyclovir and valacyclovir.

CONCLUSION
==========

In summary, clinicians need to be extra cautious when applying antiviral drugs in patients with renal failure. They need to be alert to the possible serious neuropsychiatric symptoms, need to adjust dose according to the level of renal function, pay attention to treatment course and hydration, be fully aware of the possible neurotoxicity caused by these drugs, and be aware of the good prognosis after early identification and active intervention. In the meantime, since the clearance rate of these drugs is low when using peritoneal dialysis, these patients should be switched to hemodialysis.
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